Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
CHU de Reims
120 participants
Jun 27, 2018
INTERVENTIONAL
Conditions
Summary
CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test. The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.
Eligibility
Inclusion Criteria7
- over 18 years old
- with social security affiliation
- any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids, or immunosuppressive agents
- any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation
- any serious allergy to the fluorescein sodium for injection in angiography
- any history of previous systemic anti-VEGF treatment
- any history of inflammatory or auto-immune disease
Exclusion Criteria1
- Patients with C-reactive protein CRP > 10mg/mL (serum sampling during surgery)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03680794